UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 11, 2016
AMICUS THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of
Incorporation)
|
001-33497 |
|
71-0869350 |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
1 Cedar Brook Drive, Cranbury, NJ |
|
08512 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (609) 662-2000
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On January 11, 2016, Amicus Therapeutics, Inc. (the “Company”) issued a press release (the “Press Release”) regarding its financial condition for the year ended December 31, 2015. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 7.01. Regulation FD Disclosure
Press Release
The Press Release also includes information regarding the Company’s 2015 accomplishments and its strategic outlook and financial guidance for the year ending December 31, 2016.
A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Corporate Presentations
The Company has updated its corporate presentation as of January 11, 2016. The slides from this presentation are attached hereto as Exhibit 99.2. The attached materials will be posted on the Company’s website at www.amicusrx.com. The Company does not undertake to update this presentation.
The Company presented a corporate presentation at the 3rd Annual Dermatology Summit: SD-101 for Epidermolysis Bullosa on Sunday, January 10, 2016. The slides from this presentation are attached hereto as Exhibit 99.3. The attached materials will be posted on the Company’s website at www.amicusrx.com. The Company does not undertake to update this presentation.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
|
Exhibit No. |
|
Description |
|
99.1 |
|
Press Release dated January 11, 2016 |
|
99.2 |
|
Corporate Presentation |
|
99.3 |
|
Corporate Presentation |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Amicus Therapeutics, Inc. | |
|
|
| |
|
|
|
|
|
Date: January 11, 2016 |
By: |
/s/ William D. Baird III |
|
|
|
William D. Baird III |
|
|
|
Chief Financial Officer |